Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Which index fund performed best this year? Review top performers, volatility, and potential shifts to inform your next move.
26,831 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Two collateral events in 2026 forced major Bitcoin treasuries to post large amounts of BTC to maintain loans, undersc...
A leading MIT AI researcher warns that rushing automation in Gen Z entry-level roles could undermine on-the-job learn...
As markets sway, a long-running dividend payer draws retirees seeking steady, rising income. PepsiCo's 50-plus years ...
November 2025 marks a new milestone as the Bitcoin Lightning Network surpasses $1B in monthly volume, signaling a shi...
A veteran investor warns that quantum computing could threaten Bitcoin's cryptography, arguing the real danger now is...
Celebrity relocations spotlight a bigger trend: it’s more than george. U.S. households are weighing overseas options ...
Applied Optoelectronics has jumped as AI buyers chase fast, fiber-based connectivity. The stock rally highlights how ...
A SpaceX IPO could unlock funding for a bold, space-based data center vision. This deep dive explains what data cente...
The Trade Desk is signaling a broader pivot beyond its core DSP strengths. This article breaks down how trade desk re...
Morgan Stanley warns that aggressive policy moves and a fresh oil shock could jeopardize Republicans’ hold in the Sen...
A fresh, per-capita violence ranking shifts attention away from familiar conflict zones, signaling new risk dynamics ...